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 ABSTRACT 
 
Asthma is a chronic disease affecting a significant number of patients 
worldwide, causing symptoms on the respiratory tract. 
Corticosteroids like ciclesonide are used to manage the disease. However, its 
physicochemical properties – namely water solubility – and, consequently, 
pharmacokinetics and pharmacodynamics could be object of improvement. One way 
to achieve this is by the use of cyclodextrins, a well known group of molecules able 
to include insoluble molecules, solubilising them. The aim of this work is to verify if is 
possible to obtain a dry powder for inhalation containing ciclesonide included within 
Crysmeb (a commercial type of methylated beta-cyclodextrin) applying the simple 
and inexpensive technique of kneading. The complex formed was analysed using 
ultraviolet spectroscopy, differential scanning calorimetry and infrared spectroscopy. 
Inhalation powders characteristics were assessed by time-of-flight of the particles 
(particle size analysis), and twin stage liquid impinger (aerodynamic assessment of 
fine particles). It was concluded that the kneading method is feasible for obtention 
of a ciclesonide-Crysmeb inclusion complex, although further studies would be 
desirable to optimize the process. 
Some science projects involve massive funds, time and human resources, 
having, sometimes, a relatively high risk of being unsuccessful. Therefore, using this 
experimental work as a starting point, an online questionnaire was publicized to 
science-related people from the top ten universities in the world. It was asked what 
was considered to be the most critical factors when engaging in scientific research. 
This data allowed narrowing the inputs that can be applied to ISO 31000:2009, hence 
directing an otherwise generic risk management standard to this spectrum of activity.  
The defined Risk Severity Index can also be used as a standalone tool, namely for 
individual and small organisations that do not have a risk management plan in place 
– as it was the case with this work. The methodology appears appropriate and with 
room for improvement. 
 
Keywords: Cyclodextrins, Crysmeb, ciclesonide, inhalation, risk management, 
ISO 31000:2009. 
 RESUMO 
 
A asma é uma doença crónica que afecta um número significativo de doentes 
a nível mundial, causando sintomas que a nível do tracto respiratório. 
Corticosteróides como a ciclesonida são utilizados no controlo da doença. 
Contudo, as suas propriedades físico-químicas – nomeadamente a solubilidade 
aquosa – e, consequentemente, a farmacocinética e farmacodinamia podem ser 
objecto de melhoria. Um dos modos de atingir este objectivo é através da utilização 
de ciclodextrinas, um grupo de moléculas bastante conhecido capaz de incluir no seu 
interior moléculas insolúveis, solubilizando-as. É o objectivo deste trabalho verificar 
a exequibilidade da obtenção de um pó seco para inalação contendo ciclesonida 
complexada com Crysmeb (uma forma comercial de beta-ciclodextrina metilada) 
através de um método simples e económico, a malaxagem. A formação de complexo 
foi analisada através de espectroscopia ultravioleta, calorimetria diferencial de 
varrimento e espectroscopia por infravermelhos. As características dos pós para 
inalação foram avaliadas pelo tempo-de-vôo (análise do tamanho de partícula) e 
impactador em cascata de vidro (avaliação aerodinâmica de partículas finas). Foi 
concluído que através do método de malaxagem é possível a obtenção de um 
complexo ciclesonide-Crysmeb, apesar de serem desejáveis mais estudos de modo a 
optimizar o processo. 
Alguns projectos científicos envolvem avultados montantes monetários, 
tempo e recursos humanos, tendo, por vezes, um risco de insucesso relativamente 
elevado. Assim, utilizando este trabalho experimental como ponto de partida, um 
questionário online foi publicitado junto de pessoas relacionadas com a ciência das 
dez universidades de topo, a nível mundial.  
Era questionado sobre quais os factores que consideravam ser os mais 
críticos quando iniciavam pesquisa científica. Estes dados permitiram focar os inputs 
que podem ser aplicados à ISO 31000:2009, direccionando assim uma norma de 
gestão de risco que doutro modo seria genérica a este espectro de actividade. O 
Índice da Gravidade do Risco definido pode igualmente ser utilizado isoladamente, 
nomeadamente no caso de indivíduos e pequenas organizações que não possuem 
 um plano de gestão de risco – situação que se verifica com este trabalho. A 
metodologia utilizada parece ser apropriada e com margem para melhorar. 
 
Palavras-chave: Ciclodextrinas, Crysmeb, ciclesonida, inalação, gestão do 
risco, ISO 31000:2009. 
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PART A: DOSAGE FORM – PHARMACEUTICAL DEVELOPMENT 
I – Introduction and background 
 
 
1. OBJECTIVE 
 
This part of the work has the objective of verifying the feasibility to obtain a 
drug-cyclodextrin complex, using the kneading method, formulated as a dry powder 
for inhalation. 
Specifically, the work aims to analytically confirm the formation of a drug-
cyclodextrin complex recurring to a simple physical method: kneading; and its ability to 
be formulated as dry powder for inhalation, including the in vitro delivery efficiency. 
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2. INTRODUCTION 
 
Asthma is a chronic disease affecting the respiratory tract. Circa 235 million 
people worldwide suffer from this disease, being the most common chronic disease 
among children (1). 
This disease represents a considerable health burden due to its consequential 
morbidity, mortality, and cost (2).  
Corticosteroids are widely used to manage asthma (3,4). In Portugal, 
ciclesonide is pharmacotherapeutically classified under group 5.1.3.1 – Respiratory 
system/ Antiasthmatics and bronchodilators/ Anti-inflammatories/ Glucocorticoids (5). 
Its approved therapeutical indication is the management of persistent asthma in adults 
and adolescents over twelve years old (6). Elsewhere ciclesonide is also approved for 
the therapeutic management of allergic rhinitis (7–10). 
It is well known that highly water-insoluble molecules can not be absorbed by 
the aqueous mucous layer of the lung, hence needing to be solubilized so they can 
exert their pharmacological effect (11–13). Therefore, the use of cyclodextrins appears 
to be adequate in order to improve the physicochemical properties of the drug and its 
absorption. 
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3. PATHOPHYSIOLOGY 
 
Asthma is a chronic disease involving inflammation of the pulmonary airways 
as well as bronchial hyperresponsiveness resulting in, usually reversible, lower airway 
obstruction. Factors which can trigger airway obstruction include cold air, cigarette 
smoke, respiratory allergen and upper respiratory infection of viral nature. Active 
asthma displays lamina reticularis thickening, mucus gland hypersecretion, mucosal 
edema, lung hyperinflation, smooth muscle hypertrophy, epithelial cell sloughing, cilia 
cell disruption. At a microscopic level, asthma is characterized by the presence of 
increased numbers of neutrophils, eosinophils, lymphocytes, and plasma cells in the 
bronchial tissues, bronchial secretions, and mucus. Activated T-lymphocytes direct the 
release of inflammatory mediators from lymphocytes, eosinophils and mast cells. The 
cross-linkage of two IgE molecules by allergen causes mast cells to degranulate, 
releasing leukotrienes, histamine, and other mediators that maintain the airway 
inflammation. The activated mast cells and eosinophils also generate their cytokines 
that help to perpetuate the inflammation. Regardless of the trigger, the repeated 
cycles of lung inflammation with injury to the pulmonary tissues followed by repair 
may produce long-term structural changes of the airways (14).  
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4. ACTIVE PHARMACEUTICAL INGREDIENT 
 
4.1. Physical and chemical properties  
 Physicochemical information on ciclesonide is very scarce. However, the 
following has been reported (15): 
- It is a non-halogenated glucocorticoid having the chemical name pregna-
1,4-diene-3,20-dione,16,17-[[Rcyclohexylmethylene]bis(oxy)]-11-hydroxy-
21-(2-methyl-1-oxopropoxy)-,(11β,16α)-; 
- Is a white to yellow-white powder; 
- Solubility: practically insoluble in water and freely soluble in ethanol and 
acetone; 
- The R-epimer is used in pharmaceutical preparations; 
- Its molecular weight is 540,7 Da; 
- The empirical formula is C32H44O7; 
- Has the following structural formula: 
 
Fig. 1 – Structural formula of ciclesonide (15) 
 
 
 
4.2. Pharmacology 
Ciclesonide is a pro-drug. It is enzymatically hydrolyzed in the lung via 
esterases to its pharmacologically active metabolite, C21-desisobutyryl-ciclesonide 
(des-ciclesonide or RM1), which has anti-inflammatory activity. Des-ciclesonide has 
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120 times higher affinity for the glucocorticoid receptor than the parent compound 
ciclesonide (2,4,6,15–18). 
Treatment with inhaled corticosteroids reduces the number of inflammatory 
cells in the bronchi. Among those cells are mast cells and eosinophils. They also reduce 
the proportion of alveolar macrophages and of type 2 helper T-lymphocytes and their 
related proinflammatory cytokines in asthmatic airways (3,19). 
It is thought that inhaled corticosteroids may down regulate T-cell activation 
by allergen-presenting cells, inhibiting T-cell differentiation toward the stimulation of 
IgE production as well as promotion of inflammation in general (3,20,21). This activity 
has been broadly demonstrated in vitro (3,22–25). Reasonably low doses of inhaled 
corticosteroids allow attaining not only these cellular effects, but also the respective 
therapeutic effects in asthmatic patients, representing a low risk/benefit ratio (3). 
Despite these data showing a good safety profile, the existence of some local and 
systemic side effects must still be taken into account, as some of them, namely 
oropharyngeal candidiasis, are common (3,26). 
The potency of an inhaled corticosteroid is assessed in terms of its relative 
receptor affinity when compared to the drug dexamethasone, which is assigned a 
value of 100 (2,27). An inhaled corticosteroid which possesses higher relative receptor 
affinity will induce a greater anti-inflammatory effect. Des-ciclesonide has a relative 
receptor affinity of 1200, similar to that of beclomethasone monopropionate, 1345. 
For a matter of comparison, mometasone fuorate has a relative receptor affinity of 
2300, fluticasone propionate of 1800 and budesonide of 935 (2,18). 
Ciclesonide and des-ciclesonide have a reported half-life of 0,36 hours and 
3,4 hours, respectively. Des-ciclesonide possesses a 21-hydroxyl group and, therefore 
is able to form fatty acid esters that will lead to a longer retention time in the lungs 
allowing for a longer efficacy. The formation of these lipid conjugates has not been 
related to adverse effects (18,28). 
After inhalation of a corticosteroid, a part of it is deposited in the mouth and 
oropharynx, driving to side effects such as oral candidiasis. Inhalation of a pro-drug 
may reduce the incidence of these local side effects in the mouth and oropharynx 
region, as the inactive drug that deposits in that region will be swallowed before 
activation can occur. This has been verified with ciclesonide (18). 
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5. CYCLODEXTRINS 
 
5.1. Overview  
 Carbohydrates, exempli gratia starch, cellulose and sucrose, are likely to 
be the most abundant organic compounds in nature and from very ancient time they 
have been used as food, for shelter and for clothing. Throughout times, carbohydrates 
have been processed via fermentation, as their enzymatic degradation was observed. 
These processes, we know now, originate mixtures of monosaccharides, disaccharides 
and oligosaccharides, such as linear and branched dextrins. It is also known that, when 
subjected to certain conditions, these degradation processes also originate small 
amounts of cyclodextrins (29,30). These are also known as cyclomaltoses, 
cycloamyloses or Schardinger dextrins (31,32). Table 1 presents a short  chronological 
summary on the development of carbohydrate chemistry, focusing on cyclodextrins 
(30). 
 
Table 1 – Cyclodextrins and the development of carbohydrate chemistry (30) 
 
 
Cyclodextrins were first discovered in 1891, when in addition to reducing 
dextrins a small amount of crystalline material was obtained from starch digest of 
Bacilus amylobacter. This crystalline product was named ‘cellulosine’. Later, in 1903, 
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Schardinger isolated two crystalline products, dextrins A and B. These were described 
with regard to their lack of reducing capacity (31). 
 
There are three types of cyclodextrins: alpha-cyclodextrin, beta-cyclodextrin 
and gamma-cyclodextrin, which are referred to as first generation or parent 
cyclodextrins. Alpha-, beta- and gamma-cyclodextrins are composed of six, seven and 
eight alpha-(1,4)-linked glycosyl units, respectively (31,33,34). 
They result from an intramolecular transglycosylation reaction from 
degradation of starch by cyclodextrin glucanotransferase (CGTase) enzyme (31,34). 
Depending on the type of cyclodextrin and guest compound, cyclodextrins 
can crystallise in two major types of crystal packing: cage structures and channel 
structures (31,34). 
 
Generally being the most useful, beta-cyclodextrin is the most accessible and 
the lowest-priced as well. Types of cyclodextrins properties are laid down in Table 2 
(31). 
 
Table 2 – Cyclodextrins properties (31) 
 
 
 
There are now available multiple cyclodextrin derivatives other than these 
naturally occurring cyclodextrins, that have been synthesised. The chemical reactions 
more often leading to the obtention of these derivatives are etherifications, 
aminations or esterifications of the primary and secondary hydroxyl groups of the 
cyclodextrins. These derivatives will usually alter the properties of the cyclodextrin, 
namely their solubility, stability and the volume of the hydrophobic cavity. The 
changes in the host may also play a role helping to control the activity of the guest 
molecule and the entrapment ability (31). 
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Up to 20 substituents have been linked to beta-cyclodextrin in a 
regioselective manner. To allow this to occur in a consistent manner, there is a need to 
use regioselective reagents, while optimising reaction conditions, as well as a good 
separation of products (31,34). 
 
Natural cyclodextrins and their hydrophilic derivatives are, usually, only able 
to permeate lipophilic biological membranes with considerable difficulty. Although the 
somewhat lipophilic randomly methylated beta-cyclodextrins interact more readily 
with membranes than the hydrophilic cyclodextrin derivatives, not even these 
permeate lipophilic membranes with ease (31,35). Toxicity studies have demonstrated 
that orally administered cyclodextrins are practically non-toxic, due to lack of 
absorption from the gastrointestinal tract (31,36). 
It has also been shown that short-term exposure to inhaled hydroxylpropyl-
beta-cyclodextrin, gama-cyclodextrin and randomly methylated beta-cyclodextrin 
formulations in terms of lung and renal integrity and function, as those cyclodextrins 
were non-toxic after assessing bronchoalveolar lavage, lung  and kidney histology, 
bronchial responsiveness to methacholine and blood urea (37,38). 
It is also reported that sparingly methylated beta-cyclodextrin (Crysmeb) 
presents properties allowing it to be used for inhaled drug delivery. When inhaled, 
Crysmeb has a high solubilisation capacity, transient absorption promoting properties 
and a low toxicity to the lungs (39). 
 
 
5.1.1. Inclusion complex formation 
When a drug molecule (guest) is enclosed within a cyclodextrin (host), it 
forms a drug-cyclodextrin complex or inclusion complex. The basic principle is that if 
the guest molecule is of appropriate size and shape to fit into the cavity of the host 
molecule. Therefore, stereochemistry and, probably, polarity of both the drug and the 
cyclodextrin molecules determine if the complex will occur. Thus, the complexation 
occurs in a stereospecific fashion. Due to its spatial arrangement requirements, the 
formation of the inclusion complex resembles the “lock and key” mechanism described 
for enzyme-substrate. However the guest molecule may not be included completely in 
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the cyclodextrin, leaving some part(s) of the drug molecule exposed while other are 
enclosed. When the complex is formed, the guest molecules are isolated from each 
other and are dispersed on a on a molecular level in an oligosaccharide matrix and 
cyclodextrins may be regarded as nano-encapsulating agents (40). 
The complex formation is composed by the steps shown in Fig. 2 (40). 
 
 
Fig. 2 – Formation of an inclusion complex between a drug and a cyclodextrin: 1. Displacement of polar 
water molecules from the apolar cyclodextrin cavity; 2. An increasing number of hydrogen bonds is 
formed as the displaced water returns to the pool; 3. Reduction of the repulsive interactions between 
the hydrophobic guest molecule and the aqueous environment; 4. Increase in hydrophobic interactions 
as the guest inserts itself into the apolar cyclodextrin cavity (40). 
 
In overview, complexing activity increases as the guest molecule size is 
smaller, minding that interactions keep occurring between guest and host. Similarly, 
for large molecules, their activity depends whether there is a suitable chemical group 
capable of entering the cavity of the cyclodextrin, exempli gratia, one or two benzene 
rings or larger ones carrying an aromatic moiety, a side chain or other groups of 
comparable size (40). 
The greatest percentage increase in solubility versus the concentration of 
cyclodextrin is shown for compounds with the lowest water solubility. By opposition, 
little or no effect was observed for molecules that are water soluble (40).  
However, besides inclusion complexes, cyclodextrins are also able to form 
non-inclusion complexes. Also, cyclodextrins and their complexes can form water 
soluble aggregates in aqueous solutions, which are able to solubilize water insoluble 
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active pharmaceutical ingredients, via non-inclusion complexation or micelle-like 
structures (41). 
 
Beta-cyclodextrin appears to be, among the naturally occurring cyclodextrins, 
the most useful complexing agent due to its size and availability (40). A representation 
of a beta-cyclodextrin is shown in Fig. 3 (42). 
 
 
Fig. 3 – Beta-cyclodextrin (42) 
 
The utilisation of cyclodextrins also carries the advantage of its economical 
cost as it is simpler and more economical than the majority of other available methods 
of encapsulation (40). 
 
When solubilised, inclusion complexes not always present themselves with an 
identical structure to that of the crystalline state. When in solution, the entire or part 
of the guest molecule is enclosed in the cyclodextrin with the entire complex being 
surrounded by a multilayer hydrate shell; however, when crystallised, besides the 
guest molecules that are within the cavity of the cyclodextrin, there are guest 
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molecules between the cyclodextrin rings as crystallattice inclusions, that may form 
non-inclusion complexes (40). 
 
Diverse factors may influence the formation of inclusion complexes, such as 
cavity size, temperature, method of preparation and pH and ionization state (40). 
 
5.1.2. Evaluation of Inclusion Complex Formation 
Ks, the stability or equilibrium constant, characterises the extent of 
complexation in an aqueous medium, id est, the stability of the complex formed (Eq. 1): 
 
  
                 Eq. 1 – Equation for the calculation of the stability 
constant 
 
where Kr (M-1.s-1) is the recombination rate constant and Kd (s-1) is the 
dissociation rate constant. The greater the magnitude of this ratio the greater is the 
stability of the complex (40). 
 
 
In solution, the multiple parameters relevant for the inclusion complex 
formation, such as stability constant or stoichiometry can be accurately obtained and 
the equilibrium of Eq. 1 can be altered in order to shift in the desired direction. To 
obtain this effect, some changes can be made to the environmental conditions such as 
temperature, pH, addition of a competitive molecule, concentration, polarity of the 
solvent, or even by choosing other (most) appropriate cyclodextrin or cyclodextrin 
derivative (40). 
 
According to Higuchi and Connors (43) the solubility profiles shown in Fig. 4 
can be considered. 
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Fig. 4 – Phase solubility profiles and classification of complexes according to Higuchi and Connors. S0 is 
the intrinsic solubility of the substrate (the dissolved guest/ drug) in the aqueous complexation medium 
when no ligand (cyclodextrin) is present (43). 
 
Summarising, A-type curves point to the formation of soluble inclusion 
complexes. B-type indicates the formation of inclusion compounds with poor solubility, 
where BS-type indicates complexes of limited solubility and a BI-type curve means the 
formation of insoluble complexes (40). 
On the other hand, A-type curves can be classified in AL-type, showing a linear 
increase of drug solubility as a function of cyclodextrin concentration, or; AP-type 
(positively deviating isotherms) and AN-type (negatively deviating isotherms) (40). 
KS may be obtained from the linear portion of the phase solubility diagrams 
by the following equation (Eq. 2) (40,43): 
 
Eq. 2 – Stability constant calculation, from phase solubility 
diagrams 
 
where S0 is the intrinsic solubility of the substrate on the medium. 
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However, methods other than phase solubility studies have been reported for 
the determination of KS, namely, conductometry, ultraviolet–visible 
spectrophotometry, polarography, potentiometry, microcalorimetry, circular dichroism, 
nuclear magnetic ressonance, optical rotatory dispersion, high-performance liquid 
chromatography and thin layer chromatography (40). 
 
Usually, complexes with stability constants from about 100 to 5000 M-1, seem 
to be suitable for practical applications (40). 
When the formed complex is very labile, the guest molecule will be released 
from the cyclodextrin due to the weak interaction and, therefore, not having an 
improved solubility. Conversely, very stable complexes will result in a retarded or 
incomplete release of the guest molecule, hence hindering its absorption (40). 
 
Despite what is stated above, in some cases, even with small KS values, the 
complex formation confers the active pharmaceutical ingredient better characteristics 
regarding its pharmaco-technical, physicochemical and biopharmaceutical properties. 
Usually, the inclusion complexes formed in solution have a molar ratio of host to guest 
molecules of 1:1 (40). 
 
 
5.2. Crysmeb 
 
5.2.1. General information 
Crysmeb is stable both in solution as well as in solid state; being possible 
to develop solid formulations on its basis. Crysmeb solutions, even at high 
concentrations do not originate insoluble precipitates; have a low support for 
microbial growth and is very stable under different conditions such as neutral or 
alkaline solutions. In acidic solutions Crysmeb is slowly hydrolyzed. It is stable when 
exposed to atmospheric oxygen (44). 
Crysmeb has a more specific and narrower substitution pattern than any 
other industrial derivative of beta-cyclodextrin. Whereas beta-cyclodextrin forms very 
stable crystals, reason for which has relatively low water solubility, the same does not 
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happen with Crysmeb. An approach to the beta-cyclodextrins water solubility is the 
use of its derivative hydroxypropyl-beta-cyclodextrin, where the existence of multiple 
large hydrophilic hydroxypropyl groups into all positions suitable for substitution 
prevents crystal formation. Conversely, Crysmeb has a random distribution of a few 
sterically small methyl groups into a small number of chosen positions, increasing its 
water solubility, without impairing the formation of crystals. Furthermore, since the 
methyl substituents are small they do not act as guest molecules when at high 
concentrations. (44). 
 
Crysmeb (Fig. 5 shows its crystal structure) is a mixture of methyl-beta-
cyclodextrins, which contains from one to seven methyl groups. It has, on average, 4 
methyl groups per native cyclodextrin molecule (44).  
 
 
Fig. 5 – Crystal structure of crystallized Crysmeb (44) 
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5.2.2. Physical and chemical properties  
 
Table 3 – Crysmeb physical and chemical properties (44) 
Generic name 2-O-methyl-beta-cyclodextrin 
Organoleptic characteristics Anhydrous white powder 
Molecular weight (average)* 1191 Da 
Aqueous solubility (g/100 mL) at 20ºC 20% 
Aqueous solubility (g/100 mL) at 70ºC ~65% 
Decomposition temperature >300ºC 
Moisture content ≤5% 
* - The average molecular weight is calculated with basis on the degree of molar substitution (MS) – 
average degree of molar substitution is 0,57 – of the mixture and it can be calculated as follows (Eq.3): 
 
Average Molecular Weight (Da) = 1135 + 7 x MS x 14 
 
 
 
5.2.3. Toxicity 
Regarding its toxicity, when compared to other methylated derivatives of 
beta-cyclodextrin, the low substitution degree of Crysmeb diminishes its affinity for 
cholesterol and phosphatidylcholine. Methylated-beta-cyclodextrins toxicity depends 
on a higher degree on the number and slightly on the position of the methyl groups. 
Nonetheless it still maintains good solubilizing properties for other substances. This 
selective solubilizing properties of Crysmeb for active pharmaceutical ingredients, 
rather than for lipid may be of interest, as cyclodextrins toxic consequences towards 
biological membranes, chiefly their haemolytic and cytotoxic effects, are generally 
recognised as being related to interaction with lipids (complexation and depletion) 
(45,46). 
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6. DRY POWDER INHALERS 
 
The thriving integration of medicinal products with devices able of delivering 
them to the respiratory tract in the correct doses has shown that inhalation is a 
valuable route of administration. This route allows limited systemic exposure and 
provides local topical delivery. Multiple orally inhaled medicinal products have been 
successfully developed over the last 50 years, giving symptomatic relief to millions of 
patients with respiratory tract diseases such as chronic obstructive pulmonary disease 
and asthma (47,48). 
As large doses of corticosteroids for the treatment of asthma are required for 
oral administration, these are associated with an unacceptably high adverse event 
profile (49,50). As a result of the availability of inhaled formulations, with the 
introduction of beclometasone dipropionate in 1972, inhaled corticosteroids are now 
part of the cornerstone of asthma treatment (49). 
 
During the last decades, the focus has been in the pharmaceutical 
formulation of the drug as well as in device design, aiming to respond the need for 
more efficient inhalers that can deliver larger doses to the lung while diminishing  
extrathoracic drug deposition (47,48,51). 
 
Once it is deposited in its target, the lungs, drug disposition (dissolution, 
absorption, distribution, metabolism and elimination) as well as the influence of 
pulmonary pharmacokinetics on drug efficacy and safety are the critical determinants 
of clinical outcomes (48). 
 
Despite their achievements, inhaled therapies for lung diseases are still 
restricted to a small number of classes, notably β2 agonists, antimuscarinic and 
corticosteroid drugs (48,52). 
 
Similarly to what was earlier stated, the health and economic burden of 
respiratory disease provide a massive market for inhalation drugs, and, thus the 
constant need to develop new and better inhaled medicines (48,53). 
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6.1. Drug particles deposition and absorption 
Although the mechanism by which inhaled particles are absorbed in the lung 
is not completely known, some general ideas are evident: small lipophilic  molecules 
are very quickly absorbed (within tens of seconds), typically with little metabolism; 
small hydrophilic molecules are absorbed fast (within tens of minutes), equally with 
minimal metabolism; drugs with very low water solubility can have their absorption 
retarded; peptides are rapidly absorbed and suffer significant metabolism, except if 
protected against peptidases; larger proteins are more slowly absorbed with variable 
bioavailabilities. For the intent of local lung disease applications, many small molecules 
are absorbed too quickly to produce the desired clinical outcome, the same happening 
with some systemic applications as well. A better understanding of the determinants 
of pulmonary drug dissolution, absorption, metabolism, and how to target specific 
regions and/or cells in the lung will enable safer and more effective inhaled medicines 
in the future (12). 
 
Inhaled dosage forms that deliver drug aerosols onto the lung surface in a 
solid or semisolid form are becoming increasingly common, as these systems hold the 
potential to improve the duration and effectiveness of inhaled drugs and vaccines. 
Although we have decades of experience delivering drugs systemically via the lungs 
(54), we typically describe blood levels of a drug following its inhalation. Rarely do we 
measure drug/aerosol particle persistence and location within the lungs. Ensuing 
processes after particle deposition, such as dissolution in the lung lining fluid, lateral 
spreading over the lung surface, and/or penetration within the fluids, facilitate a drug 
access to various locations in the respiratory tract. However, each of these processes is 
affected by fluid and cellular barriers and natural clearance mechanisms that operate 
in the lungs, which ultimately limit the availability and persistence of drugs within the 
lung (Fig. 6) (12). A physical structure of the tracheobronchial tree of humans (Fig. 7) 
has been proposed (48). 
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Fig. 6 – General concept of aerosol drug deposition, dissolution and absorption for local or 
systemic actions (12) 
 
 
 
Fig. 7 – Idealised geometry of the tracheobronchial tree of humans (48) 
 
 
Upon deposition in the lungs, the first interaction of drug particles is with the 
lung lining fluids (which have a total volume limited to approximately 10-30 mL), and 
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act as a protective barrier for the underlying epithelium. There, the particles must 
dissolve for subsequent absorption and/ or cellular uptake, hence the importance of 
the drug solubility (12,55,56).  
If the drug particles are not dissolved without delay in the lung lining fluids 
after depositing, it is possible they move through the fluids and further interact with 
other lung structures (12,57–59). 
 
 
6.2. Inhalers 
It is necessary an adequate and efficient delivery system – the inhaler – so 
the drug to reach the lungs. 
After aerosolisation, powders must be deagglomerated to a size small enough 
for deposition in the lungs alveolar region. 
Typically, an aerodynamic diameter between 0,5 and 5 micrometers is 
required for appropriate lung deposition. Larger particles are deposited in the 
upper airways, being swallowed or expelled. On the other hand, smaller particles 
are usually exhaled or deposited by Brownian diffusion upstream of the alveoli. 
The mechanisms that allow powder deagglomeration and dispersion are 
explained in Fig. 8. Here  there are two types of formulations of dry powders for 
inhalation (60,61). 
These powders are usually formulated for inhalation as either the active 
pharmaceutical ingredient alone or as a mixture with a carrier. The carrier chief 
purpose is to reduce the susceptibility of the fine drug particles to form strongly 
cohesive agglomerates and to increase the flowability of powders previously to 
aerosolisation (60). 
Lactose is a preferred carrier, as it does not present less advantages than, for 
example, trehalose and is inexpensive, accessible and widely used for this 
purpose (37). 
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Fig. 8 – Schematic diagram of dry powder inhaler formulation and dispersion process: A. Drug-only 
formulation (drug agglomerates); B. Carrier-based formulation. (60) 
 
 
The ideal dry powder inhaler should comprise the criteria described in Fig. 9 
(49). 
 
Fig. 9 – Criteria for an ideal inhaler (49) 
 
 
According to a survey conducted in 169 patients with respiratory disease 
(asthma or chronic obstructive pulmonary disease), the most important criterion when 
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selecting a dry powder inhaler is its ease of use. Even if a dry powder inhaler 
demonstrates an outstanding pharmaceutical performance regarding drug output, if it 
is not correctly used then it can be rendered ineffective. If patients are unable to use 
the inhaler as directed, their treatment is compromised which may lead to severe 
consequences (49,62). 
 
When compared to pressurised metered-dose inhalers, dry powder inhaler 
devices have an intrinsic advantage over the former, given that the dose of drug is only 
expelled from the inhaler as the patient inhales it. As a result, it is not necessary the 
patients coordination between the inspiration and the actuation of the device. 
Nonetheless, the patient still has to provide a sustained and adequate inspiratory flow 
rate through the inhaler in order to get the complete drug dose to be released from 
the device (49). 
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 II – Materials and methods 
 
1. OBJECTIVE 
The objective was to develop a ciclesonide-Crysmeb complex by kneading and, 
analytically, confirm its formation and characteristics. 
 
2. MATERIALS, REAGENTS AND EQUIPMENTS 
All reagents used were of analytical grade. 
Crysmeb: Roquette Pharma as KLEPTOSE CRYSMEB. 
Ciclesonide: Hovione. 
All materials, reagents and equipments used in this work were provided to 
the author by the Faculty of Pharmacy of the University of Lisbon. 
The 0,22 micrometer pore syringe filters used were from Millipore. 
Ultraviolet spectroscopy was performed with a Hitachi U-2000 
spectrophotomer, using quartz cells. The DSC Q200, TA Instruments was used to obtain 
the thermograms. Infrared spectroscopy analysis was made with an IRAffinity, 
Shimadzu. Particle size analysis was carried out using an Aerosizer LD – Amherst 
process instruments, Inc. 
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3. METHODS 
 
3.1. Calibration curve and detection limits 
A calibration curve is used so that an unknown concentration of a given 
solution can be determined. The method used for the construction of the calibration 
curve was ultraviolet spectroscopy, since this method will be used throughout the 
work to perform assays (40). 
Firstly, a wavelength scan was performed to evaluate the peak absorption for 
ciclesonide, using an hydroalcoholic solution (equal volumes of water and ethanol), 
once the molecule of interest, ciclesonide, is highly insoluble in water but soluble in 
ethanol. Then the calibration curve followed – for the same reason as stated previously, 
an hydroalcoholic solution was used. Ciclesonide solutions were prepared with 
concentrations ranging from 0,0025 mg/mL to 0,05 mg/mL, at regular intervals. 
 
3.2. Phase solubility studies 
Aiming to identify the solubility profile of the complex, phase solubility 
studies were performed in accordance with the method proposed by Higuchi and 
Connors (43). 
Briefly, to aqueous solutions of increasing concentrations of cyclodextrin an 
excess of drug was added and the suspension was shortly vortexed. The mixtures were 
then kept under agitation at 25ºC and the drug excess was assured until equilibrium 
was attained. Cyclodextrin concentration ranged from 0 to 0,125 M and aliquots were 
retrieved at 30 minutes, 2 hours, 8 hours, 24 hours, 48 hours and 72 hours. The 
aliquots were then filtered through a 0,22 µm pore filter, so that the suspended drug 
was not measured in the ultraviolet spectroscope, but only the molecules included in 
the cyclodextrin. The filtrate was then diluted with an equal volume of ethanol and 
measured at 242 nm – the reference cell of the spectroscope was an hydroalcoholic 
solution of cyclodextrin, with equal cyclodextrin concentration of that of the diluted 
sample. This was performed to ensure that no signal from the cyclodextrin was being 
measured, as wavelength scans of cyclodextrin solutions showed interference at 
higher concentrations. 
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3.3. Preparation of the powders for inhalation 
The powders were prepared by kneading. 
Four different powders were attained, varying the amount of water used for 
kneading and molar ratio of drug-to-cyclodextrin: 
 
Powder A – 1:1 M (drug:cyclodextrin), 50 % (m/m) water 
Powder B – 1:1 M (drug:cyclodextrin), 90 % (m/m) water 
Powder C – 1:2 M (drug:cyclodextrin), 50 % (m/m) water 
Powder D – 1:2 M (drug:cyclodextrin), 50 % (m/m) water 
 
For powders A and B, equimolar quantities of cyclodextrin and drug were 
mixed in a porcelain mortar, by hand, adding successively the respective amounts of 
water (50% m/m for powder A and 90% m/m for powder B). 
The same procedure was followed for powders C and D, varying only the 
molar proportion of drug-to-cyclodextrin, which is 1:2. 
From this point on all powders were treated equally.  
Powders were thoroughly kneaded for 15 minutes, time at which they 
presented as an apparently dry mass. They were then kept over night in a dessicator at 
room temperature. Subsequently, the masses were scrapped from the porcelain 
mortar and transferred to a glass mortar where they were pulverized during 5 minutes 
and passed through a 63 micrometers sieve. 
Physical mixtures (1:1 M and 1:2 M) of drug:cyclodextrin were also prepared. 
The powders were then analyzed regarding their physicochemical properties 
by ultraviolet spectroscopy, differential scanning calorimetry and infrared 
spectroscopy. A portion of the powders were also mixed with sieved lactose 
3,5%:96,5% powder:lactose (m/m) – these proportions were based on previous data 
(37). 
 
After prepared according to the description above, the powders went 
through a set of analytical procedures, so that their physicochemical properties could 
be assessed. 
The following techniques were applied: 
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3.4. Ultraviolet spectroscopy 
This method was used for the assay of every powder/ mixture. 
Every solution tested was measured against the appropriate reference, 
namely concerning their concentration in cyclodextrin. 
 
3.5. Differential scanning calorimetry 
The powders were subject to calorimetric analysis using the ramp method for 
temperature increase, ranging from 35ºC to 300ºC (at a rate of 10ºC/minute). The 
analysed powders were A, B, C, D, physical mixtures drug:cyclodextrin (1:1 M and 1:2 
M), cyclodextrin alone and ciclesonide alone. 
Also washed powders were analysed: A’, B’, C’ and D’. In brief, the washing 
process consists of an amount of powder that is resuspended in water, after which the 
mixture is filtered and the filtrate is dried at 60ºC during 24 hours to recover the solid 
inclusion complex. This allows the removal of the insoluble ciclesonide particles that 
were not included and remained in suspension. 
The cyclodextrin and the drug, separately, were also tested, under the same 
conditions, in order to be used as a reference. 
 
 
3.6. Infrared spectroscopy 
Disks of potassium bromide with the analyte, were prepared; and analysed at 
a wavelength between 0 and 4000 cm-1 (63). 
Powders assessed were: A’, B’, C’ and D’, ciclesonide and cyclodextrin.  
 
 
3.7. Particle size profile analysis 
Particle size analysis was carried out by the method of time-of-flight. In this 
method particles are accelerated their times-of-flight are measured across two laser 
beams taking into account the sample density (64). 
Powders A, B, C and D were measured. Were also measured powders A, B, C 
and D mixed with sieved lactose (63 μm sieve) at a ratio of 3,5% powder to 96,5% 
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lactose (mass percentage) – Mixtures A, B, C and D. Powders A, B, C and D were also 
measured, before sieving, to evaluate the need for that final action. 
These samples did not require any prior special preparation and were directly 
measured. 
 
 
3.8. Aerodynamic assessment 
Samples consisted of gelatine capsules manually filled with the equivalent 
amount of 160 µg of active pharmaceutical ingredient (corresponding to 3,5% of the 
active substance to 96,5% of lactose (m/m)), as follows: 
Powder A – 26,15 mg/ capsule; 
Powder B – 26,20 mg/ capsule; 
Powder C – 36,29 mg/ capsule; 
Powder D – 35,71 mg/ capsule. 
 
Five capsules of each powder were, cumulatively, used and the experiment 
was performed according to the current edition of the European Pharmacopoeia. 
Shortly, the twin stage liquid impinger device is put under an air flow of 60 L.min-1 and 
the powder was discharged from the capsule via a dry powder inhaler (the Microhaler® 
was used for these experiments). The discharge of each capsule is maintained for a 
period of 5 seconds. At different stages of the apparatus hydroalcoholic solution [50:50 
(V/V)] was used. The apparatus was then disassembled, washed thoroughly with the 
appropriate solvent and those solutions were assayed. Every stage, except the lower 
one with a final volume of 50 mL, were washed up to a final volume do 20 mL (65).  
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4. RESULTS AND DISCUSSION 
 
4.1. Calibration curve and detection limits 
The chosen technique for assaying every preparation was ultraviolet 
spectroscopy. Ultraviolet spectroscopy has been extensively used for this and multiple 
other purposes. It is based on the absorption of a specific radiation wavelength by a 
given molecule (40,66–68). Hence, a calibration curve for ciclesonide was firstly 
obtained.  
Being that the drug is highly insoluble in water, hydroalcoholic standard 
solutions of ciclesonide were prepared. 
Performing a wavelength scan, the peak for the ciclesonide hydroalcoholic 
solution was found to be 242 nm (Graph 1). 
 
Graph 1 – Wavelenght scan for ciclesonide solution 
 
Following the determination of absorvance for known concentrations of 
ciclesonide in hydroalcoholic solutions, a calibration curve was obtained (Graph 2). The 
correlation coefficient (R2) determined, close to the unit, indicates a good linearity, 
showing that absorbance values within that interval can be adequately applied to the 
model. 
The segment where linearity was obtained represents a lowest measurable 
drug concentration limit of 0,0025 mg/mL and a highest concentration limit of 0,05 
mg/mL of ciclesonide hydroalcoholic solution. These values revealed adequate for the 
assays performed. 
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Graph 2 – Calibration curve for ciclesonide 
 
4.2. Phase solubility studies 
Phase solubility studies were performed to determine at what time 
equilibrium was found and to calculate the complex stability constant as well as the 
stoichiometry for the inclusion process. 
Subsequently to the determination of drug concentration in each sample, 
Graph 3 was plotted. From its analysis it is possible to verify that dynamic equilibrium 
was achieved at 48 hours, and the drug concentration in solution stabilised from that 
point on. 
 
 
 39 
Drug concentration (M) vs.  Time (hours)
0
0,001
0,002
0,003
0,004
0,005
0,006
0,007
0 10 20 30 40 50 60 70 80
Time (hours)
D
ru
g 
co
n
ce
n
tr
at
io
n
 (M
) 5 mM
20 mM
50 mM
100 mM
125 mM
 
Graph 3 – Phase solubility studies at different times 
 
Graph 4, relating drug concentration versus cyclodextrin concentration was 
also plotted. 
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Graph 4 – Drug concentration versus cyclodextrin concentration 
 
Considering the linear portion of data at 48 hours (dynamic equilibrium 
achieved) from Graph 4, a new graph was plotted (Graph 5), for the determination of 
the solubility constant.  
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Graph 5 – Ks and complexation stoichiometry determination 
 
The linear regression model showed to fit the real data (R2 = 0,9992), 
therefore suggesting an AL-type curve. 
Ks was calculated to be 14880,033 M-1, applying the before mentioned 
formula (Eq. 2): 
 , with slope = 0,0289; S0 = 2x10
-6 M 
Eq. 2 – Stability constant calculation, from phase solubility diagrams 
 
The ultraviolet method was unable to detect the drug low concentrations 
when Crysmeb concentration was null. Also, the literature did not provide a definitive 
answer regarding what was the intrinsic solubility of ciclesonide. Hence, S0 was 
calculated from the interception of the curve from the linear regression with the yy 
axis of Graph 5. 
The linear relation obtained supports that complexation occurred in a 1:1 M 
(drug:cyclodextrin) stoichiometric fashion. The obtained stability constant value of 
14880,033 M-1 points to a very stable inclusion complex, which might hinder drug 
release from the complex. However, this might be of interest if aiming, for example, at 
a modified release dosage form. 
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Despite phase solubility studies point towards a 1:1 M (drug:cyclodextrin) 
stoichiometry, powders were prepared at both 1:1 M and 1:2 M (drug:cyclodextrin) 
stoichiometry. 
 
 
4.3. Preparation of the powders for inhalation 
The kneading process, including sieving, had the following yields (Table 4): 
 
Table 4 – Powder yield 
Powder Yield (% m/m) 
A 40,9 
B 41,3 
C 49,1 
D 42,5 
   
This method shows the same yield as other methods, having several 
advantages, such as being more economic and less time consuming to obtain the 
complex (69). 
 
 
4.4. Ultraviolet Spectroscopy 
 
4.4.1. Inclusion efficiency and drug content determination 
Subsequent to their obtention powders A, B, C and D were assayed both before 
and after washing, to allow determining the inclusion efficiency. 
Results are shown in Table 5: 
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Table 5 – Inclusion efficiency 
Assay (mg/mL) 
 
Regular Washed 
Inclusion efficiency (%) 
Powder A 0,0926 0,0154 16,65 
Powder B 0,0924 0,0098 10,59 
Powder C 0,0708 0,0091 12,84 
Powder D 0,0715 0,0121 16,87 
 
The same data was also used to determine drug content of each powder, id 
est, what amount of active pharmaceutical ingredient is present in each mixture, either 
included within the cyclodextrin or free – Table 6. 
 
Table 6 – Drug content determination 
 
Solution concentration 
(mg/mL) 
Assay 
(mg/mL) 
Drug content 
(mg/g) 
Drug percentage 
(% m/m) 
Powder A 0,53 0,0926 174,72 17,5 
Powder B 0,53 0,0924 174,34 17,4 
Powder C 0,56 0,0708 126,43 12,6 
Powder D 0,56 0,0715 127,68 12,8 
 
The first parameter of the powders verified was the yield (table 4). In fact, 
this parameter is not very reliable nor conclusive as, at laboratorial level, working with 
minimal amounts, there are great percentages of mass losses. Visible mass losses 
occur mainly when transferring the kneaded mass to the pulverizing mortar and, 
afterwards, when sieving the powder. 
The determined inclusion efficiency (Table 5) is not very high. This might be due to the 
need of more kneading time as fifteen minutes seem not to be sufficient to achieve 
higher inclusion efficiency. Further studies on this matter can be conducted to 
evaluate if the kneading process or the host/ guest characteristics are the limitative 
steps themselves for the achieved inclusion efficiency or if the kneading parameters 
might be changed towards a better inclusion efficiency. However, bearing in mind that 
 43 
the proposed formulation includes not only the complexed active substance, but also 
free ciclesonide, it might not be considered a draw back, as no active pharmaceutical 
ingredient is discarded. This characteristic may even be of interest for controlling the 
pharmacokinetic profile of the drug. Taking in consideration the steps taken before the 
measurement, as described previously, these determinations were also a first pointer 
(although indirect) that an inclusion complex was obtained by kneading, as the active 
substance was identified even after samples were suspended in water alone and then 
filtered. Being a nearly water-insoluble drug, if not included within the cyclodextrin, 
the active pharmaceutical ingredient could have not been detected by ultraviolet 
spectroscopy or, even if some free drug molecules might dissolve, considering the drug 
water solubility, the concentration would be below the detection limit. Corresponding 
drug content of the powders were also determined (Table 6). 
 
4.5. Proof of complex formation 
 
4.5.1. Differential scanning calorimetry 
Cyclodextrin complex formation can be verified differential scanning 
calorimetry, as an endothermic peak is observed for the molecule (equivalent to its 
melting or boiling point) and for the physical mixture but will be absent for the 
complex (40). Thermograms obtained by differential scanning calorimetry were used 
to determine if an inclusion complex by kneading was indeed formed. 
Thermograms obtained are presented in Fig. 10 and Fig. 11: 
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Fig. 10 – Thermograms for: a) Crysmeb; b) ciclesonide; c) powder A; d) 
powder B; e) powder C; f) powder D. 
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f) 
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Fig. 11 – Thermograms for: a) powder A’; b) powder B’; c) powder C’; d) 
powder D’; e) physical mixture 1:1 M (drug:cyclodextrin); f) physical 
mixture 1:2 M (drug:cyclodextrin). 
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f) 
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The characteristic endothermic peak for ciclesonide (melting point circa 210 
ºC) is present in the thermograms of the powders A, B, C and D (Fig. 10, c) to f)) – id est, 
it seems there is still some amount of free drug; but this peak is absent in the washed 
powders (Fig. 11, a) to d)) – id est, only inclusion complex is present and no free 
ciclesonide. 
In the physical mixtures the same peak is visible (Fig. 11, e) and f)). 
Crysmeb has a characteristic endothermic peak at approximately 210ºC (Fig. 
10 a)), while ciclesonide presents its characteristic endothermic peak at around 75 ºC 
(Fig. 10 b)). Tested samples results also point to the formation of an inclusion complex 
by the kneading method, as the kneaded and washed samples (A’ B’, C’ and D’) (Fig. 11, 
a) to d)) presented only the endothermic peak corresponding to cyclodextrin (although 
slightly shifted or with different intensity), while the physical mixtures (Fig. 11, e) and 
f)) and unwashed powders (Fig. 10, c) to f)) showed both endothermic peaks. As 
discussed previously, these kneaded and washed samples (A’ B’, C’ and D’) were 
assayed, confirming that there was indeed included active substance within the 
cyclodextrin. 
 
 
4.5.2. Infrared Spectroscopy 
Some types of complex formation may be demonstrated by infrared 
spectroscopy. Bands, due to the included portion of the guest molecule, are generally 
shifted or their intensities altered (40). 
Following the obtention of thermograms, which already shown the inclusion 
complex formation, as discussed above, this analysis was performed to further verify 
the occurrence of drug:cyclodextrin complex formation. Powders A, B, C and D were 
not used, as the intent was to confirm the inclusion complex formation, that is masked 
in these powders, as they contain free drug as well.  
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The above mentioned spectra are presented as follows: 
 
Graph 6 – Crysmeb; 
Graph 7 – Ciclesonide; 
Graph 8 – powder A’; 
Graph 9 – powder B’; 
Graph 10 – powder C’; 
Graph 11 – powder D’; 
Graph 12 – powders A’, C’, drug, Crysmeb; 
Graph 13 – powders B’, D’, drug, Crysmeb; 
Graph 14 – powders A’, B’, C’ and D’. 
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Graph 6 – Infrared spectrum of Crysmeb 
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Graph 7 – Infrared spectrum of ciclesonide 
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Graph 8 – Infrared spectrum of powder A’ 
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Graph 9 – Infrared spectrum of powder B’ 
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Graph 10 – Infrared spectrum of powder C’ 
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Graph 11 – Infrared spectrum of powder D’ 
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Graph 12 – Infrared spectra of powders A’, C’, ciclesonide, Crysmeb 
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Graph 13 – Infrared spectra of powders B’, C’, ciclesonide and Crysmeb 
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Graph 14 – Infrared spectra of powders A’, B’, C’ and D’ 
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One possible interpretation for the infrared spectrum of ciclesonide (Graph 6) 
is adapted from the work proposed by Feth et al. (70) – table 7: 
 
Table 7 – Interpretation of the infrared spectrum for ciclesonide 
Peaks (cm
-1
) Proposed assignment 
3387 
(strong, broad) 
O-H stretch vibration in 
secondary alcohols 
2968-2853 
(strong, sharp) 
-CH2- and CH3- asymmetric and 
symmetric stretch vibrations 
1746, 1728 
(strong, sharp) 
C=O stretch vibrations of 
ketones and esters 
1653 
(strong, sharp) 
C=O stretch vibration of α, β 
unsaturated carbonyls 
1616, 1603 
(medium, sharp) 
C=C stretch vibrations of α, β 
unsaturated carbonyls 
1470-1362 
(medium, sharp) 
-CH2- and CH3- asymmetric and 
symmetric deformation 
vibration of methyl, isopropyl 
and cyclohexyl groups 
1240 
(medium, sharp) 
C-O stretch vibrations in esters 
1188-1059 
(short, sharp; medium, 
sharp) 
C-O stretching in secondary 
alcohols and asymmetric C-O-C-
O-C stretch vibrations in 
acetates 
821 
C=C-C=O out of  plane  
deformation vibration 
787, 696 -CH2- rocking vibration 
 
Analysing graphs 12 to 14 it is noticeable that none of the identified 
characteristic peaks from the drug (ciclesonide) is visible in powders A’, B’, C’ and D’ – 
the peaks from the said powders correspond to those from Crysmeb. 
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As predictable from the thermograms results, the obtained spectra reveal the 
formation of an inclusion complex. As visible in Graphs 12 to 14, characteristic peaks of 
ciclesonide – Table 7 – are not present in any of the samples, except for the ciclesonide 
sample itself (Graph 6). Powders A’, B’, C’ and D’ showed a transmittance pattern 
similar to those of cyclodextrin, only with some changes in the peaks intensities. Thus, 
these results provide confirmation that an inclusion complex of drug-cyclodextrin is 
formed. 
 
4.6. Particle size profile analysis 
Particle size analysis was performed to evaluate particle size distribution – a 
major aspect for inhalation powders. 
Analysed samples are shown in Fig. 12 and Fig. 13: 
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Fig. 12 – Graphs for particle size analysis for the different samples 
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Fig. 13 – Graphs for particle size analysis for the different samples 
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Table 8 shows the parameters determined for the powder samples. 
Table 8 – Particle size analysis results 
 
Mean size 
(µm) 
% under 5 
µm 
D% under 5 µm 
(µm) 
D90 
(µm) 
D50 
(µm) 
D10 
(µm) 
Span 
(µm) 
Powder A 2,38 80 4,24 6,27 2,24 1,01 2,35 
Powder B 2,42 80 4,35 6,14 2,32 1,04 2,20 
Powder C 2,59 80 4,94 7,53 2,44 1,03 2,66 
Powder D 2,55 80 4,60 6,56 2,47 1,05 2,23 
Powder A 
(before sieving) 
2,19 80 4,75 6,60 2,19 0,73 2,68 
Powder B 
(before sieving) 
2,44 80 4,64 6,37 2,41 0,93 2,26 
Powder C 
(before sieving) 
2,41 80 4,67 6,26 2,40 0,92 2,23 
Powder D 
(before sieving) 
2,29 80 4,44 6,23 2,27 0,85 2,37 
Mixture A 2,65 80 4,41 5,88 2,59 1,23 1,80 
Mixture B 2,67 85 4,97 5,69 2,67 1,25 1,66 
Mixture C 2,70 80 4,65 6,28 2,67 1,18 1,91 
Mixture D 2,70 80 4,60 6,36 2,61 1,21 1,97 
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4.7. Aerodynamic assessment 
The last test performed was the aerodynamic assessment of fine particles of 
mixtures A, B, C and D – the twin stage liquid impinger provides information regarding 
the expected amount of powder deposited along the respiratory tract. The equivalent 
mass of the powders to 160 µg of active pharmaceutical ingredient was determined by 
assaying the above mentioned powders. The powders used were A, B, C and D instead 
of A’, B’, C’ and D’ (washed powders), so that no active pharmaceutical ingredient was 
lost, even if not included within the cyclodextrin – cost minimisation of the formulation. 
Capsules containing a nominal dose of 160 µg of ciclesonide were tested 
accordingly to the European Pharmacopoeia. 
Results are shown on table 9: 
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Table 9 – Aerodynamic behaviour results 
Twin Liquid 
Impinger stages 
Average filling 
weight (mg/ 
capsule) 
Total active 
substance 
content (mg) 
Active substance 
recovery (% m/m) 
Lower stage 26,18±2,84 
Middle stage 50,03±3,79 
Upper stage 18,77±2,84 
Capsule + 
inhaler device 
9,06±3,07 
Mixture A 
Total 
26,3 0,8 
104,03±12,54 
Lower stage 25,76±2,84 
Middle stage 42,89±3,20 
Upper stage 18,95±2,98 
Capsule + 
inhaler device 
12,04±3,47 
Mixture B 
Total 
26,4 0,8 
99,65±12,49 
Lower stage 17,63±3,08 
Middle stage 54,35±3,21 
Upper stage 11,96±2,85 
Capsule + 
inhaler device 
14,15±3,13 
Mixture C 
Total 
 
36,2 
0,8 
98,09±12,27 
Lower stage 17,38±3,09 
Middle stage 54,48±3,23 
Upper stage 12,01±2,86 
Capsule + 
inhaler device 
14,21±3,14 
Mixture 
D 
Total 
35,7 0,8 
98,19±12,33 
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It is clear the marked decrease (around 35%) of drug deposition in the lower 
stage of the liquid twin impinger in mixtures C and D when compared to the remaining 
powders. 
Mixtures A and B, which have less cyclodextrin, present higher amount of 
powder deposition in the lower stage, corresponding to the lung level. On the other 
hand, formulations C and D display roughly less 9% of drug deposition in the lower 
stage. Considering the data from the particle size analysis, although mixtures A and B 
have presented a slightly higher percentage of fine powders (< 5 micrometers), as well 
as an almost marginal lower mean particle size, these factors do not seem to differ 
enough to justify lower stage deposition percentage variations. It can, however, be 
hypothesized that mixtures C and D, having twice the amount of cyclodextrin of 
mixtures A and B, can have a poorer flowability. This because Crysmeb molecules are 
large, having a molecular weight of 1,191 kDa, consequently with higher adhesion and 
cohesion forces between them forming agglomerates that hamper the mixtures route 
until the lower stage (71). Also, being a carbohydrate, when in contact with humidified 
surfaces it may originate a viscous solution, which adheres to the upper glass surfaces 
of the apparatus. The obtained results, namely for the lower stage, positively differ 
from those presented, for example, elsewhere by Marques and Schmidt (72), 
representing a good aerodynamic behaviour profile of the mixtures. 
No major difference was found among formulations beside the deposition 
percentage of mixtures A and B versus C and D; thus, mixture A, stands out as the 
better choice, since it has the best aerodynamic behaviour and is better or comparable 
to the remaining ones regarding the other parameters tested, with the lowest amount 
of excipients. 
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5. CONCLUSION 
 
It can be concluded that is feasible to produce a drug:cyclodextrin complex 
with ciclesonide and Crysmeb, recurring to the simple and inexpensive method of 
kneading. This method allowed to obtain a drug:cyclodextrin complex with a 
reasonable inclusion efficiency and a good aerodynamic behaviour, suitable for lung 
administration via inhalation. However, further studies to enhance the kneading 
process, so that parameters like yield and inclusion efficiency can be enhanced. 
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PART B: RISK MANAGEMENT 
Directing a risk management model to scientific research 
 
 
OBJECTIVE 
The objective was to develop a tool that could be used integrated within a 
risk management plan or by itself, to support decision-making when facing risks during 
scientific research projects. 
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INTRODUCTION 
 
This one, like any other scientific research and development project, presents 
a risk for every stakeholder. 
While initially outlining this work, soon became obvious that it was 
susceptible be affected by both internal and external factors that could hinder the 
work progress. Therefore, the need to evaluate which factors and how they could 
affect Part A of the work arose. This requirement led to the design of a more 
comprehensive approach. Hence it was decided to add Part B to this thesis, where a 
more in-depth characterization of the factors that affect scientific research was made. 
This approach resulted in an investigation that expanded itself beyond this 
particular work, although including it, as it is a science research project. It was so 
decided that the focus should not be exclusively on this work. Instead, we proposed to 
develop a tool that could provide not only information to guide our research, but to be 
an input for existing risk management plans and international standards. 
 
Taking into account the high monetary costs involved, time spent and social 
relevance, research projects – namely the drug-related ones – should be built upon a 
risk management plan. 
Although tools like ISO 31000:2009 already exist (73), these end up being of 
general application, meaning they can be applied to such a range of activities that span 
from, exempli gratia, aircraft manufacturing to stockbroking, hence not specific for life 
sciences research and development. Thus, a tool specially designed for this purpose, 
taking into account the input of the main stakeholders, presents itself as a more 
appropriate approach. 
 
In research and development oriented organisations, ensuring that multiple 
projects are executed simultaneously and timeliness, meaning the development of the 
right products at the right times, is a subject of serious consideration. Taking into 
account that research and development is a cardinal to the organisation, and their 
interaction within the remaining activities of the institution are dynamic,  it is highly 
challenging to undertake such projects (74). 
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Technological innovation is not only one of the important key strategies for 
high technology firms but also a social imperative for scientific research and 
development institutions, as their work usually reflects, either directly or indirectly, on 
peoples lives and quality of life (75–77). 
However, different types of innovation entail different degrees of uncertainty 
that may originate unsuccessful research and development projects (77–82). 
Taking the pharmaceutical industry as an example, the success rate of a drug 
development project, since the first human testing to its marketing authorisation, is 
under 10%. Bearing in mind the financial burden these and other research and 
development projects carry, it is important to have planned ahead how to manage 
risks for these projects throughout all the development stages, so their success rates 
are improved (77,83–85). 
 
Generally, risk management is a structured approach which has been widely 
applied in many fields, such as management, engineering, insurance, finance, 
environment and politics for the identification, assessment, and prioritization of risks. 
Following these steps there should be a planning of activities and resources to 
minimize, monitor, and control the likelihood of undesirable events and, if they occur, 
their impact on the organisation and its stakeholders (77,83). In the setting of research 
and development projects, the main objective of risk management is to raise success 
rate of the project, which will, ultimately, lead to the institution success (77,81,84,86–
89). The main problem in risk management is that if the risks are improperly identified 
and prioritized, that can reflect in time and cost wasted in dealing with risk of losses 
(77,81,83,84,87,89,90).  
 
Risk has multiple definitions which vary according to the different application 
domains. In project management, there is no consistent definition for risk (77,90,91). 
Although some, consider risk as ‘‘an uncertain event or condition that, if it occurs, has 
a positive (opportunity) or negative (threat) impact on project objectives.’’, others, 
mostly practitioners and researchers in project management, continue to consider risk 
being more related to adverse effects on project performance (77,83,91–93). From this 
point of view, risk management appears to be related to the identification and 
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management of threats to the project. Moreover, in the literature, uncertainty is also 
defined as randomness of the environment, inability to foresee the impacts of 
environmental change, and powerlessness to predict the consequences of choice 
(77,80,94,95). Risk is, as well, frequently defined as undesired project outcomes and 
exposure to uncertainty (77,81,83,84,86,87,89).  
 
Managing the risk in research projects to enhance its success rates has been 
subject studies for many years and widely applied in practice, showing that applying 
risk management techniques to innovative research and development projects is able 
to improve their success rates (77,80,81,83,84,86,93,96–99). 
 
The principles and guidelines for effective risk management and the 
importance of active risk management for accelerating projects and improving their 
success rates have previously been described. It has also been shown that risk 
management practice is more applicable for higher-risk projects (77,81,86). 
 
Some studies have developed risk management approaches to select the 
proper projects for increasing success rates of product launch and to capture the 
business opportunity and attain profit for the company (77,100–102). However is still 
noticeable a lack of research on providing an integrated framework that takes into 
account operational risk management and provides a methodical approach for risk 
identification, assessment, response planning, and control (77). 
 
In this context, ISO 31000:2009 plays a major role outlining the main 
requirements which a risk management plan should comprise to be effective for any 
organisation or activity and thus providing a backbone for the development of specific 
risk management policies. 
ISO 31000:2009 approaches risk management in view of several aspects that, 
although generically applicable, are well described within the document itself. In 
summary, the text describes the dialectics involved in identifying, analysing, evaluating 
and mitigating the risk inside an organisation in a transparent and robust manner. 
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This International Standard recognizes that every sector or application has its 
own individual needs and criteria. Hence, it places the establishment of context as a 
key feature to help revealing and assess the nature and complexity of the risks, by 
capturing the organisation objectives, the environment in which these objectives are 
pursued, its stakeholders and the specific risk criteria. 
The context in which an organisation operates is a key factor for the 
performance of their operation.  
Establishing the context comprises the following items, that jointly allow to 
establish the framework for any organisation (73): 
1) External context – it is based on the organisation context as a whole. 
Regarding scientific research, major external factors may include legal, regulatory, 
technological and financial/ economic issues; 
2) Internal context – risk management should be aligned with the 
organisation culture, structure, processes and overall strategy. Internally, factors to 
take into account when establishing the context may encompass governance, structure, 
policies, objectives and human and financial capabilities; 
3) Context of the risk management process – it should be established to 
which activities, objectives and parameters risk management is applied. Objectives, 
responsibilities, scope, depth and methodologies for the risk management process 
should be clearly defined; 
4) Risk criteria definition – this item relates to the significance of risk 
evaluation. Factors to achieve this purpose may include characterization of 
consequences, definition of acceptable risk and definition of likelihood. 
 
The following steps of a risk management plan, according to ISO 31000:2009, 
relate to risk assessment. Namely, risk identification, risk analysis and risk evaluation. 
Risk identification concerns to the recognition of risks that might affect the 
organisation or project; risk analysis purpose is to provide an input for risk evaluation, 
as this step analyses the causes of the risk, their consequences and likelihood of those 
consequences; on the other hand, the object of risk evaluation is to compare the level 
of different risks, prioritize them and come to a decision of whether or not there is the 
need to take action. 
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Identifying specific risks for scientific research and defining which ones are 
more likely to occur and which ones have more impact allows directing an otherwise 
generic set of risk management standards to the practice of science. Therefore, this is 
the focus of our work: introducing knowledge regarding the specificities of scientific 
research. This will allow a narrower application of the International Standard with 
verifiable practical effects on risk management. 
 
Remaining steps of ISO 31000:2009, such as risk treatment, monitoring and 
review or recording of the risk management process will not be dealt with on this work. 
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METHOD AND TOOLS 
 
In order to assess what is considered to have more impact and to be more 
likely in this setting, an online form (Annex I) was created. 
In short, the questionnaire inquired about the respondents formation, place 
of work and what factors they considered critical when starting a new research project. 
The factors available for choice were based on a first questionnaire (Annex II) sent only 
to a reduced number of investigators, who gave their input. Similar responses were 
then categorized and grouped, and each group was presented in the public form as a 
distinct option. 
Impact evaluation was made directly from raw data, as it was asked for the 
respondents to rank what they considered to be the critical factors, id est, the ones 
with more impact. To avoid a lengthy questionnaire, it was chosen not to ask directly 
about the probability of each factor, which was estimated from the frequency of each 
option. 
The online form was sent to individual emails collected from the websites of 
the world top ten universities (103): University of Cambridge (United Kingdom), 
Harvard University (United States of America), Massachusetts Institute of Technology 
(United States of America), Yale University (United States of America), University of 
Oxford (United Kingdom), Imperial College of London (United Kingdom), University 
College London (United Kingdom), University of Chicago (United States of America), 
University of Pennsylvania  (United States of America) and Columbia University (United 
States of America). The form was also published in some relevant groups (professional, 
alumni and institutional groups) on social and professional networks, namely 
Facebook® and LinkedIn®. 
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RESULTS AND DISCUSSION 
 
Considering only sent emails, the response rate was 15,2%. It is, however, 
reasonable to consider the real response rate lower, as the form was also present in 
social/ professional networks; this is also reinforced by the fact that some replies were 
from countries other than the United Kingdom or the United States, home to the 
universities of where the emails were sent. 
Total number of replies was 76, of which 68 were considered valid, 
corresponding to a percentage of 89,5. For a form to be considered valid, it had to 
meet two criteria: adequate response to all mandatory questions; and the respondent 
was related with scientific research. 
Graphs 15, 16 and 17 represent, respectively, basic training, workplace and 
location of the respondents. 
Basic training
Biochemist/ Biologist
16%
Chemist
6%
Medical doctor
7%
Nurse
4%
Pharmacist
46%
Other
21%
 Graph 15 – Basic training of the respondents 
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Workplace
Healthcare facility
24%
Private research 
organisation
10%
Public research 
institution
7%
Regulatory authority
4%
University
30%
Other
25%
 Graph 16 – Workplace of the respondents 
 
 
 
Graph 17 – Location of the respondents  
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Core data regarding the critical factors when engaging in scientific research 
acquired from the questionnaires was used to define a Risk Severity Index as described 
in the literature; where Risk Severity Index is described as Impact X Probability (104). 
Impact was calculated the following way: 
1. Crescent numbers were assigned from the fifth to the most critical 
factor (from 1 to 5); 
2. The frequency of each factor was then multiplied by its corresponding 
number and the values obtained per factor were added; 
3. Based on the sum of each factor, an arbitrary value was specified for 
each one – to the highest sum it was given the number 12, the second 
highest the number 11 and so on. 
 
Likelihood was calculated considering the relative frequency of each factor. 
Based on it, an arbitrary value was specified for each one. 
Having calculated both the Likelihood and the Impact, is possible to assess 
the Risk Severity Index, according to the above mentioned formula. 
 
After Risk Severity Index was calculated for each factor identified, one, two 
and three thirds percentile were calculated, so risk categories could be assigned to 
each factor, taking into account its Risk Severity Index. 
Results are shown on table 10. 
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Table 10 – Risk Severity Index/ Risk Category 
Factor Risk Severity Index Risk Category 
Location 4 
Qualified human resources 9 
Scientific area 15 
Economical outcome 16 
N
o
n
cr
it
ic
al
 
Professional prospectives 35 
Publishing potential 36 
Scientific method 56 
Logistics 56 
C
ri
ti
ca
l 
Coordination with colleagues/ superiors 81 
Timespan/ planning of the project 100 
Funding 121 
Objectives/ potential applications 144 V
er
y 
cr
it
ic
al
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The method chosen for data collection – an online questionnaire – had some 
advantages: 
- It allowed a worldwide participation, with replies from people based in five 
continents, namely Africa, America, Asia and Europe; comprising different work 
cultures and standards; 
- Access to investigators in top universities, that otherwise would not be 
accessible to this project; 
- Could be easily shared; 
- Simplified data treatment.   
 
The questionnaire was designed so its structure could provide data to 
determine: 1) which risk factors are present on scientific research; 2) what is the 
likelihood of their occurrence and; 3) should they occur, at what level the organisation 
would be affected. 
The likelihood of their occurrence versus their impact is called Risk Severity 
Index. This index (Table 10) is semi-quantitative, dividing risk into three categories: 
very critical, critical and noncritical. 
 
Taking into account that the Risk Severity Index was calculated based on the 
opinion of a pool of experts, we consider it to be reliable for use as a “guideline” within 
the International Standard. Therefore, science-oriented organisations implementing a 
risk management plan, may find this information useful to be applied in the scope of 
and within ISO 31000:2009, namely when describing some of its points: definition of 
risk criteria, risk analysis and risk evaluation. This means that the input generated by 
this data can, ultimately, define how, when and if the organisation should address a 
given risk; with a more robust basis of support. 
Despite its greatest usefulness is achieved when integrated in a risk 
management plan, data obtained can also be used as a standalone tool. 
 
In this case, as no risk management plan was in place – nor deemed 
necessary – Risk Severity Index was used as an individual tool to follow the project 
progress. It allowed to direct efforts and manage time and resources, while conducting 
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Part A of this work. This way, decision-making on whether a risk should be dealt with 
primarily or its treatment could be postponed, was based taking into account not only 
the individual experience, but – most importantly – the collective one. 
 
Despite other risks that always exist, the one that was mostly perceived from 
the beginning and during the work, was the time frame for its conclusion. So, faced 
with this risk, three major paths could be followed: 1) address the problem as soon as 
possible; 2) postpone treatment of the risk or; 3) disregard the risk. 
Based on individual experience and context, it was decided this matter should 
be addressed as soon as possible. This assessment was also supported by what is laid 
down in Table 10. 
Being the only identified risk, the approach was straightforward: address it as 
soon as possible. However, should there be a multiplicity of risks with limited 
resources to address them all simultaneously, along with no experience of the 
situation and/ or context, the calculated Risk Severity Index is a valuable tool to define 
how to act. Information provided by the Risk Severity Index, helps to identify – 
together with a risk management plan, if it exists – how the organisation should 
primarily direct its resources, to address which risks: 
- Very critical risks – should be addressed firstly and concentrate the 
organisation resources. These risks are those more likely to occur and more damaging 
to the organisation. 
- Critical risks – should be addressed after very critical risks. Medium 
likelihood and impact to the organisation. 
- Noncritical risks – last to be addressed. Present minimal chance of occurring 
with minimal effects upon the organisation. 
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 CONCLUSION 
 
The method applied allowed to obtain data that could be treated to be used 
as a standalone tool or as a part of a risk management plan. 
The Risk Severity Index determined for scientific research is a useful tool for 
organisations that work within this scope of activity. It allows them to better 
appreciate how to address risks, especially when the organisation has little experience 
with them. It provides a hierarchy, so that when multiple risks are encountered, a good 
resources management can be put in place, minimising hazardous consequences for 
the project and/or organisation. 
This index, used as an individual tool also shows valuable for individuals or 
smaller organisations, that do not have a risk management plan. It points on where to 
act first and more actively, even if not within the frame of an integrated plan. 
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CONCLUSION AND FUTURE OUTLOOK 
 
Despite using a simple and inexpensive process, it was possible to obtain an 
inclusion complex of drug-cyclodextrin. This may reveal useful for the pharmaceutical 
industry as a simple process might reduce the needed amount of active 
pharmaceutical ingredient to produce the desired therapeutic effects. Further studies 
could improve the kneading process, making it more efficient. 
A directed risk management approach to scientific research is an added value 
for every project. Data acquired during this work shows to be promising as it includes 
the views of top scientists and is focused in this specific area. However, it is desirable 
that the sample would be larger to include the maximum number of expert opinions, 
providing a more balanced scoring of the Risk Severity Index. 
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